C12N9/26

CLEANING COMPOSITIONS COMPRISING DISPERSINS IX

Non-limiting cleaning compositions may include a mix of enzymes including dispersins and specific amylases or mannanases. Said compositions may be used in cleaning processes and/or for cleaning of items, such as textiles, as well as methods of using said compositions for removal or reduction of organic stains.

SUCROSE INVERTASE VARIANTS

The present disclosure provides sucrose invertase variants having an enhanced ability to hydrolyze sucrose into glucose and fructose and related methods and compositions.

THERAPEUTIC ADENO-ASSOCIATED VIRUS COMPRISING LIVER-SPECIFIC PROMOTERS FOR TREATING POMPE DISEASE AND LYSOSOMAL DISORDERS

Recombinant AAV (rAAV) vectors comprising a rAVV genome comprising a heterologous nucleic acid encoding a lysosomal protein, e.g., acid alpha-glucosidase (GAA) polypeptide, and optionally a signal peptide and/or optionally a targeting sequence, e.g., IGF2 targeting peptide, operatively linked to a liver-specific promoter (LSP), enabling the GAA polypeptide to be secreted from the liver and targeted to the lysosomes. Particular embodiments relate to a recombinant AAV (rAAV) vector encoding an alpha-glucosidase (GAA) polypeptide, having a liver secretory signal peptide and a IGF2 targeting peptide that binds human cation-independent mannose-6-phosphate receptor (CI-MPR) or to the IGF2 receptor, permitting proper subcellular localization of the GAA polypeptide to lysosomes. Also encompassed are cells, and methods to treat a lysosomal disease, for example, a glycogen storage disease type II (GSD II) disease and/or Pompe Disease with the rAAV vector.

LYSOSOMAL TARGETING AND USES THEREOF
20180009904 · 2018-01-11 ·

The invention provides compositions and methods for effective lysosomal targeting mediated by PCSK9. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Pompe Disease and Sanfilippo Syndrome Type B, and they may be used for targeting lysosomal enzymes to the various muscles of the human body.

A MILK ANALOGUE PRODUCT COMPRISING CEREAL AND LEGUME

The present invention relates to a vegan food composition comprising at least 5 wt % cereal and at least 10 wt % legume on a dry basis, wherein said composition comprises at least 2 wt % dietary fiber provided by cereal and legume and at least 5 wt % protein provided by any one or more of said cereal and legume, and wherein the D4,3 particle size of said composition is less than 100 microns.

PROCESS FOR PRODUCING ETHANOL FROM RAW STARCH USING ALPHA-AMYLASE VARIANTS

The present invention relates to raw starch hydrolysis and in particular to a raw starch hydrolysis and fermentation process. More particularly the present invention relates to a process of producing a fermentation product from raw starch material, comprising the steps of: (a) saccharifying starch-containing material at a temperature below the initial gelatinization temperature of said starch-containing material; and (b) fermenting with a fermenting organism, wherein step (a) is carried out using at least a variant alpha-amylase comprising a substitution at one or more positions corresponding to positions 196, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 28, 38, 39, 43, 54, 56, 57, 64, 67, 68, 70, 71, 86, 89, 90, 94, 96, 99, 101, 103, 107, 108, 110, 113, 114, 117, 127, 134, 138, 142, 150, 151, 152, 156, 169, 171, 174, 179, 183, 193, 199, 200, 204, 205, 207, 208, 209, 212, 218, 221, 222, 224, 233, 241, 245, 259, 275, 278, 281, 282, 283, 284, 285, 308, 323, 335, 348, 359, 382, 386, 388, 392, 394, 396, 412, 414, 417, 424, 428, 457, 459, 466, 479, 489, 511, 533, 534, 542, 543, 545, 547, 549, 550, 551, 560, 566, 570, 574, 575, 576, 577, 578, 580, 581, 582, 589, 592, 599, 603, 605, 608, 614, 619, or 626 of the polypeptide of SEQ ID NO: 1, wherein the variant has alpha-amylase activity and wherein the variant has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, but less than 100% sequence identity, to the polypeptide of SEQ ID NO: 1, and optionally a glucoamylase.

NOVEL SIGNAL PEPTIDES GENERATED BY ATTENTION-BASED NEURAL NETWORKS
20230234989 · 2023-07-27 ·

The disclosure provides for artificial signal peptides generated by systems and methods utilizing deep learning.

MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS

Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

ALPHA-AMYLASE VARIANTS
20230227803 · 2023-07-20 ·

Disclosed are compositions and methods relating to variant alpha-amylases. The variant alpha-amylases are useful, for example, for starch liquefaction and saccharification, for cleaning starchy stains in laundry, dishwashing, and other applications, for textile processing (e.g., desizing), in animal feed for improving digestibility, and for baking and brewing.

Nucleic Acids, Vectors, Host Cells and Methods for Production of Beta-Fructofuranosidase from Aspergillus Niger

The present invention provides nucleic acids, vectors, host cells and methods for production of beta-fructofuranosidase from Aspergillus niger. The invention represents an advancement in the field of genetic engineering and provides methods for obtaining high yield of a novel recombinant β-fructofuranosidase encoded by fopA gene of Aspergillus niger as a secreted protein.